AstraZeneca today announced that the US Court of Appeals issued a temporary injunction against the US launch of a generic version of its mainstay heartburn drug Nexium.
AstraZeneca has operations in Delaware.
The agreement came after AstraZeneca entered into an agreement with Hanmi Pharmaceutical and affiliates to streamline litigation issues regarding Hanmi’s proposed product.
Under terms of the agreement, Amneal and Hanmi conceded the validity of two patents that protect Nexium.
In July 2013, AstraZeneca filed a Notice of Appeal in the US Court of Appeals regarding aspects an earlier decision.
In early August, Hanmi Pharmaceuticals received US FDA approval for its Esomeprazole Strontium product.